NAGE
NASD Niagen Bioscience, Inc.$2.71 ↓ -0.01 (-0.37%) Trading Down from the previous close of $2.72, $0.04 below the day’s high of $2.76
- YTD change
- -57.39%
- vs 20-day SMA
- -8.17%
- vs 200-day SMA
- -36.61%
Price ranges
Price & Performance
-1.78 (-39.82%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 81.6% away from all-time highs of $14.69
- NAGE is down 57% since the beginning of the year
- NAGE is down 62% over the past 12 months
- NAGE is down 13% over the past 1 month
- 9% of all NAGE investors are betting against NAGE
NAGE reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -62.5%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -8.14%
- vs 8-day SMA
- -4.66%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, Analytical Reference Standards and Services, and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The Pharmaceuticals segment focuses on the pharmaceutical development of NAD precursor portfolio for potential therapeutic applications in rare diseases. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
